Top Markets
Coin of the day
Intellipharmaceutics International Inc. Intellipharmaceutics International Inc.

Intellipharmaceutics International Inc.

IPCIF
Rang in Aktien #99999
Intellipharmaceutics International Inc., a pharmaceutical company, researches,... Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. It also provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. In addition, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.
Aktienkurs
$0.15
Marktkapitalisierung
$4.96M
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
CA
Handel Intellipharmaceutics International Inc. (IPCIF)

Kategorie

Operative Marge für Intellipharmaceutics International Inc. (IPCIF)
Operative Marge zum March 2026 TTM: -4,336.82%
Laut den neuesten Finanzberichten und dem Aktienkurs von Intellipharmaceutics International Inc. beträgt die aktuelle operative Marge (TTM) -4,336.82%. Am Ende des Jahres 2021 lag die operative Marge bei -4,336.82%.
Historie der operativen Marge von Intellipharmaceutics International Inc. von 1999 bis 2026
Operative Marge zum Jahresende
Jahr Operative Marge ändert
2026 (TTM) -4,336.82% 0.00%
2022 -4,336.82% 0.00%
2021 -4,336.82% 1,356.53%
2020 -297.75% -10.80%
2019 -333.80% -57.10%
2018 -778.07% 418.13%
2017 -150.17% -65.75%
2016 -438.41% 152.31%
2015 -173.76% 331.38%
2014 -40.28% -90.98%
2013 -446.40% -95.27%
2012 -9,447.17% 509.60%
2011 -1,549.72% 273.68%
2010 -414.72% 0.00%
2009 0.00% 0.00%
2008 0.00% 0.00%
2007 0.00% 0.00%
2006 0.00% 0.00%
2005 0.00% 0.00%
2004 0.00% 0.00%
2003 0.00% 0.00%
2002 0.00% -100.00%
2001 -1,046,045.90% 42.56%
2000 -733,774.14% 13,744.82%
1999 -5,299.99% 0.00%
Operative Marge vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Operative Marge Differenz der operativen Marge Land
41.30% -100.01%
DK
35.45% -100.01%
US
24.95% -100.01%
US
25.32% -100.01%
BE
25.64% -100.01%
NL
Was ist die operative Marge eines Unternehmens?
Die operative Marge ist ein wichtiger Indikator zur Bewertung der Rentabilität eines Unternehmens. Höhere operative Margen sind in der Regel besser, da sie zeigen, dass ein Unternehmen seine Produkte oder Dienstleistungen mit deutlichem Gewinn über den Produktionskosten verkauft. Die operative Marge wird berechnet, indem der Gewinn des Unternehmens durch seinen Umsatz geteilt wird.